University scientists get rare US approval for drug trials

A new twist on a traditional treatment for chronic constipation developed by scientists at a university in Hong Kong has become the first Chinese medicine botanical drug to win approval for clinical trials in the United States, writes Sammy Heung for the South China Morning Post.

Baptist University’s Centre for Chinese Herbal Medicine Drug Development (CDD) on Sunday 6 August said the decision was a major landmark that could lead to its treatment breaking into the global market. Professor Bian Zhaoxiang, the university’s associate vice-president and the director of the clinical division of the School of Chinese Medicine, said the US trials, approved by the Food and Drug Administration (FDA), would start later this year. “Authorisation from the FDA is a milestone in the development of Chinese medicine in Hong Kong,” Bian, also the director of the CDD, told the Post.

Bian said it was hoped to introduce the new medicine, CDD-2101, to the US market in four to six years. He added no Chinese medicine had been approved by the FDA to be sold in the US market and no more than eight had been approved for clinical trials.
Full report on the South China Morning Post site